Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC.
Target Price
The average target price of SPRB is 239 and suggests 187% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell